Plant molecular pharming in Africa for sustainable health and economic development
Open Access
- 11 December 2025
- journal article
- review article
- Published by Springer Nature in Vegetos
- p. 1-10
Abstract
Plant genetic engineering goes back to over 40 years ago with the first genetically modified tobacco expressing the nopaline synthase gene. Since then, genetic engineering has emerged as an important technology as various sectors have included it in their strategic plans with potential impact on healthcare, agriculture and industry. One important aspect is the engineering of plants as bioreactors for production of vaccines, monoclonal antibodies, pesticides, orphan drugs, dyes and many other recombinant novel products. This process is referred to as plant molecular pharming. Plant molecular pharming has numerous benefits over conventional methods such as the use of animal cell lines and prokaryotic systems to produce recombinant products. These benefits include cost effectiveness, rapid and high mass production, easy scalability, accessibility and sustainability. Some African countries such as South Africa have adopted plant molecular pharming and have increased human and infrastructural capacity development, collaborations, and public sensitisation coupled with enabling policies and regulatory frameworks. However, in most of Africa, the sector faces numerous challenges including the lack of funding and expertise, low public acceptance, and poor to inadequate polices and regulatory frameworks. Despite the caveats surrounding the technology, it remains a significantly important tool for addressing global health challenges and fostering biotechnology innovations. Therefore, this review explores plant molecular pharming methods and associated products, advantages, strategies taken to improve the technology, regulatory and social- economic issues surrounding the technology in Africa.Keywords
Funding Information
- Bernhard-Nocht-Institut für Tropenmedizin
This publication has 71 references indexed in Scilit:
- Viral Nanoparticles‐Mediated Delivery of Therapeutic CargoAdvanced Therapeutics, 2023
- Inactivation of the β (1, 2)-xylosyltransferase and the α (1, 3)-fucosyltransferase gene in rice (Oryza sativa) by multiplex CRISPR/Cas9 strategyPlant Cell Reports, 2021
- A simplified techno‐economic model for the molecular pharming of antibodiesBiotechnology and Bioengineering, 2019
- CRISPR/Cas9-mediated knockout of the RDR6 gene in Nicotiana benthamiana for efficient transient expression of recombinant proteinsPlanta, 2019
- Synthetic gene design—The rationale for codon optimization and implications for molecular pharming in plantsBiotechnology and Bioengineering, 2016
- Progress in Vaccine DevelopmentCurrent Protocols in Microbiology, 2015
- Fighting Ebola with ZMapp: spotlight on plant-made antibodyScience China Life Sciences, 2014
- Good Manufacturing Practices (GMP) and Related FDA Guidelines2007
- High expression of foot-and-mouth disease virus structural protein VP1 in tobacco chloroplastsPlant Cell Reports, 2005
- Commercial production of transgenic Bt insect-resistant cotton varieties and the resistance management for bollworm (Helicoverpa armigera Hubner)Chinese Science Bulletin, 2000